A
Power Law company profile
Abcam
Biotech & Life Sciences · Cambridge, United Kingdom · Founded 1998 · IPO 2005 Unicorn
Valuation
$5.30B
Market cap · 2026
Revenue
$477M
Latest reported FY
Global footprint
Where Abcam has talent and traffic
AI talent share
0.7%
of workforce is AI talent
(13 of 1,885 staff)
(13 of 1,885 staff)
Core AI30.16%
Other AI100.53%
Non-AI workforce1,87299.31%
Web traffic by country
670K
monthly visits
across markets
across markets
🇺🇸 United States28.7%
🇬🇧 United Kingdom10.6%
🏳️ Korea6%
🏳️ Republic of3.5%
🇨🇳 China3.4%
Patent intelligence
$49M patent portfolio · 31 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$49M
0.92% of market cap · 16× smaller than top peer BioNTech ($780M)
31 active patent families
Where Abcam innovates
Molecular biologyCell biologyAntiendomysial antibodiesBiochemistrySite-specific recombination
Above peer median on Legal, Strategic, Market
Quality vs same-sector peers
Abcam on the five Patsnap quality dimensions
Abcam in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Abcam concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Abcam and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Abcam on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.